Cargando…

Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance

This cross-sectional study evaluates changes in the rate of germline BRCA testing among patients with ovarian cancer between 2008 and 2018 and analyzes factors associated with testing rates.

Detalles Bibliográficos
Autores principales:	Cham, Stephanie, Landrum, Mary Beth, Keating, Nancy L., Armstrong, Joanne, Wright, Alexi A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753497/ https://www.ncbi.nlm.nih.gov/pubmed/35015069 http://dx.doi.org/10.1001/jamanetworkopen.2021.42703

Ejemplares similares

Assessment of Patient Attribution to Care From Medical Oncologists, Surgeons, or Radiation Oncologists After Newly Diagnosed Cancer
por: Gondi, Suhas, et al.
Publicado: (2021)

BRCA germline mutation test for all woman with ovarian cancer?
por: Paradiso, A. V., et al.
Publicado: (2019)

Practice-Level Variation in Molecular Testing and Use of Targeted Therapy for Patients With Non–Small Cell Lung Cancer and Colorectal Cancer
por: Roberts, Thomas J., et al.
Publicado: (2023)

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer
por: Eccleston, Anthony, et al.
Publicado: (2017)

Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer
por: Bekos, Christine, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer
por: Jang, Jaehyeok, et al.
Publicado: (2023)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?
por: Nguyen-Dumont, Tu, et al.
Publicado: (2020)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

Utilization, Timing, and Outcomes of BRCA Genetic Testing Among Women With Newly Diagnosed Breast Cancer From a National Commercially Insured Population: The ABOARD Study
por: Armstrong, Joanne, et al.
Publicado: (2021)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

BRCA1 and BRCA2 Germline Mutations Screening in Algerian Breast/Ovarian Cancer Families
por: Cherbal, Farid, et al.
Publicado: (2010)

Social Risk Adjustment of Quality Measures for Diabetes and Cardiovascular Disease in a Commercially Insured US Population
por: Nguyen, Christina A., et al.
Publicado: (2019)

BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families
por: Claes, K, et al.
Publicado: (2004)

Screening for germline rearrangements in BRCA1 and BRCA2 in Norwegian families with breast or breast/ovarian cancer
por: Van Ghelue, M, et al.
Publicado: (2005)

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome
por: Ashour, Mohamed, et al.
Publicado: (2019)

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
por: Przybytkowski, Ewa, et al.
Publicado: (2020)

Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients
por: Zhang, Yunuo, et al.
Publicado: (2022)

A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention
por: Hanley, Gillian E., et al.
Publicado: (2018)

Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
por: Kwon, Janice S., et al.
Publicado: (2022)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom
por: Akaev, Iolia, et al.
Publicado: (2021)

Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2
por: Barbosa, Ana, et al.
Publicado: (2020)

Evaluation of Reliability and Correlations of Quality Measures in Cancer Care
por: Keating, Nancy L., et al.
Publicado: (2021)

Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017
por: Benedict, Kaitlin, et al.
Publicado: (2020)

Opportunities for Savings in Risk Arrangements for Oncologic Care
por: Landon, Bruce E., et al.
Publicado: (2023)

A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival
por: Bolton, KL, et al.
Publicado: (2012)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
por: Wineland, Dylane, et al.
Publicado: (2023)

Prevalence of Immunosuppressive Drug Use Among Commercially Insured US Adults, 2018-2019
por: Wallace, Beth I., et al.
Publicado: (2021)

Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations
por: Jorge, Soledad, et al.
Publicado: (2019)

Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status
por: Logue, Chloe A., et al.
Publicado: (2021)

Trends in Testosterone Prescriptions for Older Men Enrolled in Commercial Insurance and Medicare Advantage
por: Everhart, Alexander, et al.
Publicado: (2021)

Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer
por: Cao, Wen-Ming, et al.
Publicado: (2016)

Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer
por: Nicolussi, Arianna, et al.
Publicado: (2019)

Germline mutations in 5’ to c.7914 of BRCA2 significantly increase risk of prostate cancer
por: Ruan, Xiao-Hao, et al.
Publicado: (2022)

Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing
por: Vlessis, Katherine, et al.
Publicado: (2019)

Trends in Infertility Care Among Commercially Insured US Women During the COVID-19 Pandemic
por: Zhou, Beth, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d8p79l3saqo2aa4suftn4ng7kn